Replies to post #93735 on Biotech Values

[DewDiligence]

Edoxaban approved in Japan for VTE prevention following orthopedic surgery:

http://finance.yahoo.com/news/Daiichi-Sankyo-Receives-First-prnews-2197766739.html?x=0&.v=1

The technical merits and drawbacks of Edoxaban are similar to those of Pradaxa: qD dosing for the general patient pool (good) and dose reduction for patients with renal impairment (bad).

Edoxaban would be a much more widely discussed competitor to Xarelto, Apixaban, and Pradaxa if not for the lateness of the ex-Japan development program. The worldwide phase-3 trial in VTE prevention began in Feb 2010 (#msg-46218043) and the worldwide phase-3 trial in AF/stroke prevention began in Dec 2010 (#msg-46218043), so it will be a couple of years at least before Edoxaban can be launched in the US and EU.

p.s. The new brand name, Lixiana, has an ‘x’ and two ‘a’s, which seems appropriate for a Factor Xa inhibitor :- )